Improving Gout Care After an ED Visit
ConditionGout
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-99
SponsorUniversity of Alabama at Birmingham
About this trial
The prevalence of gout has been steadily increasing over several decades and is correlated with the rising burden of obesity, chronic cardiac and renal disease; all conditions overrepresented in the Southeastern U.S. - particularly in African Americans. Through a novel post-emergency department visit intervention, we aim to improve the care patients with gout receive, both during acute exacerbations and long-term. A secondary goal of the project is to concurrently enhance participation of minorities in biomedical research in the Deep South.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
≥ 18 years old
Able to communicate and understand English or Spanish
Confirmed acute gout flare by EMR review at ED visit
Disqualifiers
Enrollment in an ongoing RCT (NCT04075903) testing a behavioral intervention employing "storytelling".
Trial design
Design model
Parallel
Treatments tested in this trial
Patient Navigation
BehavioralA lay patient navigator working will contact patients seen in the UAB ED via phone within \~72 hours following the ED visit. During this initial phone conversation, the navigators will: 1) conduct a baseline assessment to identify barriers to attending an outpatient visit for gout care and to adhering to gout treatment recommendations and 2) determine the level of support and assistance needed by the patient.
Treatment groups
200 Participants
are divided into 2 treatment groupsGroup A: Patient NavigationExperimental treatment 1 intervention
Group B: ControlNo intervention 0 interventions
Trial outcomes
Primary outcomes
1
Follow-Up Visit Addressing Gout within 3 Months
Proportion of patients that have a follow-up visit addressing gout in the 3-month period after the ED visit.
Time frame
3 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov